IP Library › Granted Patent US 12,312,615
Granted Patent B2
US 12,312,615 · App. 17/514,585 · Granted May 27, 2025

Lipid-encapsulated dual-cleaving endonuclease for DNA and gene editing

Inventors: David R. Edgell (London, CA); Thomas A. McMurrough (London, CA); Brent E. Stead (Toronto, CA); Odisho K. Israel (Toronto, CA)
Assignee: SPECIFIC BIOLOGICS INC.
C12N9/22A61K31/7088A61K38/465C12N15/11C12N15/907C12N2310/20C12N2800/80
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,312,615
App. No.
17/514,585
Granted
May 27, 2025
Kind
B2
Abstract

Provided herein are modified Staphylococcus aureus Cas9 nucleases and methods of using modified Staphylococcus aureus Cas9 nucleases. Also provided herein are chimeric nucleases comprising an I-Tevl nuclease domain, and a Staphylococcus aureus Cas9 and methods of using the chimeric nuclease. Also provided herein are methods to edit genes by administering a chimeric nuclease to a cell or organism without the use of a viral vector.

Claims (19)

1. A method to edit genomic DNA of a mammalian cell comprising the step of administering a chimeric nuclease, the chimeric nuclease comprising a modified Enterobacteria Phage T4 (I-TevI) nuclease domain, a linker, an RNA-guided nuclease Staphylococcus aureus Cas9 and a guide RNA to the cell, thereby editing the genomic DNA of the cell, wherein the RNA-guided nuclease Staphylococcus aureus Cas9 comprises the sequence of SEQ ID NO: 13 with an aspartic acid to glutamic acid substitution at an amino acid corresponding to position 10 of SEQ ID NO: 13.

2. The method of claim 1 , wherein the cell is derived from an organism and cultured ex vivo.

3. The method of claim 1 , wherein a CFTR gene of the cell is targeted by the chimeric nuclease.

4. The method of claim 3 , wherein the chimeric nuclease targets and cleaves 10 to 20 nucleotides on either side of the CFTR delta F508 mutation.

5. The method of claim 1 , wherein the linker comprises one or more of the group consisting of SEQ ID NOS: 7 to 12.

6. The method of claim 1 , wherein the chimeric nuclease is encapsulated in a lipid nanoparticle.

7. The method of claim 1 , wherein the Staphylococcus aureus Cas9 additionally comprises an amino acid mutation at an amino acid position corresponding to position 557 of SEQ ID NO: 13.

8. The method of claim 1 , wherein the Staphylococcus aureus Cas9 additionally comprises an amino acid mutation at an amino acid position corresponding to position 840 of SEQ ID NO: 13.

9. The method of claim 1 , wherein the I-Tevl nuclease domain comprises the amino acid sequence set forth in SEQ ID NO: 6.

10. The method of claim 9 , wherein, the I-Tevl nuclease domain comprises a substitution or deletion of the methionine at position 1 of SEQ ID NO: 6.

11. The method of claim 1 , wherein the guide RNA comprises a nucleic acid sequence set forth in SEQ ID NO: 15 or SEQ ID NO: 21.

12. The method of claim 3 , wherein the cell is from a subject with cystic fibrosis.

13. The method of claim 3 , wherein the chimeric nuclease cleaves a CFTR gene containing the CFTR Delta F508 mutation, but not a CFTR gene containing the wild-type CFTR sequence.

14. The method of claim 1 , wherein the method further comprises contacting the cell with an exogenous donor DNA.

15. The method of claim 14 , wherein the donor DNA is single stranded DNA.

16. The method of claim 14 , wherein the donor DNA is double stranded DNA.

17. The method of claim 14 , wherein the donor DNA comprises homology arms.

18. The method of claim 1 , wherein the cell is a mammalian cell.

19. The method of claim 18 , wherein the cell is a human cell.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 18, 2022
From: EDGELL, DAVID R.; MCMURROUGH, THOMAS A.; STEAD, BRENT E.; ISRAEL, ODISHO K.
To: SPECIFIC BIOLOGICS INC.
Reel/Frame 059305/0432 →
Continuity (4)
Continuation PCTIB2020054229 · May 4, 2020
Provisional Application 62842586 · May 3, 2019
Provisional Application 63019423 · May 3, 2020
Related Publication 20220195404A1 · Jun 23, 2022
References Cited (31)
US 8865406B2 · Zhang et al. · 2014 [cited by applicant]
US 10196651B2 · Conway · 2019 [cited by examiner]
US 11491207B2 · Khalili et al. · 2022 [cited by applicant]
US 11814658B2 · Edgell · 2023 [cited by examiner]
US 20230016280A1 · Edgell · 2023 [cited by examiner]
US 20230203464A1 · Edgell et al. · 2023 [cited by applicant]
US 20240150796A1 · Stead · 2024 [cited by examiner]
WO 2013068845A2 · 2013 [cited by applicant]
WO 2014093622A2 · 2014 [cited by applicant]
WO 2014121222A1 · 2014 [cited by applicant]
WO 2017049407A1 · 2017 [cited by applicant]
WO 2017165859A1 · 2017 [cited by applicant]
WO 2018071868A1 · 2018 [cited by applicant]
WO 2018136396A2 · 2018 [cited by applicant]
WO 2018237369A2 · 2018 [cited by applicant]
WO 2019060469A2 · 2019 [cited by applicant]
WO 2020225719A1 · 2020 [cited by applicant]
Whisstock et al., “Prediction of Protein Function From Protein Sequence”, Q. Rev. Biophysics., 2003, vol. 36 (3): 307-340, 2003, 307-340. [cited by applicant]
Nishimasu et al., “Crystal Structure of [cited by applicant]
Vakulskas et al., “A High-fidelity Cas9 Mutant Delivered as a Ribonucleoprotein Complex Enables Efficient Gene Editing in Human Hematopoietic Stem and Progenitor Cells”, Nature Medicine, Aug. 2018, 24(8):1216-1224. [cited by applicant]
Chang et al. (Mar. 19, 2019) “Integrating Combinatorial Lipid Nanoparticle and Chemically Modified Protein for Intracellular Delivery and Genome Editing”, Accounts of Chemical Research, 52(3):665-675 (24 pages). [cited by applicant]
Guha et al. (Nov. 29, 2017) “Applications of Alternative Nucleases in the Age of CRISPR/Cas9”, International Journal of Molecular Sciences, 18(12):2565 (13 pages). [cited by applicant]
Wang et al. (Aug. 20, 2018) “Delivery of The Cas9 or TevCas9 System into Phaeodactylum Tricornutum via Conjugation of Plasmids From a Bacterial Donor”, Bio-protocol Journal, 8(16):e2974 (14 pages). [cited by applicant]
Wishart et al. (Nov. 10, 1995) “A Single Mutation Converts a Novel Phosphotyrosine Binding Domain into a Dual-Specificity Phosphatase”, The Journal of Biological Chemistry, 270(45):26782-26785. [cited by applicant]
Witkowski et al. (Sep. 7, 1999) “Conversion of a Beta-Ketoacyl Synthase to a Malonyl Decarboxylase by Replacement of the Active-Site Cysteine with Glutamine”, Biochemistry, 38(36):11643-11650. [cited by applicant]
Wolfs et al. (Dec. 12, 2016) “Biasing Genome-Editing Events Toward Precise Length Deletions With an Rnaguided Tevcas9 Dual Nuclease”, Proceedings of the National Academy of Sciences of the United States of America, 113(… [cited by applicant]
International Preliminary Report on Patentability for Application No. PCT/IB2020/054229, mailed on Nov. 9, 2021, 8 pages. [cited by applicant]
International Search Report and Written Opinion for Application No. PCT/IB2020/054229, mailed on Jul. 29, 2020, 16 pages. [cited by applicant]
Keskin, et al. (2004) “A New, Structurally Nonredundant, Diverse Data Set of Protein—Protein Interfaces and its Implications”, Protein Science, 13:1043-1055. [cited by applicant]
Moses, et al. (Mar. 18, 2019) “Applications of CRISPR Systems in Respiratory Health:entering a New ‘Red Pen’ Era in Genome Editing”, Respirology, 24(7):628-637. [cited by applicant]
Pakula, et al. (1989) “Genetic Analysis of Protein Stability and Function”, Annual Review of Genetics, 23:289-310. [cited by applicant]
Cited By (1)
US 12,460,192